Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
出版年份 2014 全文链接
标题
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
作者
关键词
-
出版物
BLOOD
Volume 124, Issue 4, Pages 511-518
出版商
American Society of Hematology
发表日期
2014-05-24
DOI
10.1182/blood-2014-03-566323
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
- (2013) P. Neelakantan et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Activated platelets can deliver mRNA regulatory Ago2bulletmicroRNA complexes to endothelial cells via microparticles
- (2013) B. Laffont et al. BLOOD
- Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
- (2013) Andrew M Stein et al. BMC CANCER
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
- (2013) T D Kim et al. LEUKEMIA
- Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
- (2013) F J Giles et al. LEUKEMIA
- Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
- (2012) C. Massard et al. ANNALS OF ONCOLOGY
- BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
- (2012) S. Branford et al. BLOOD
- Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
- (2012) J. Guilhot et al. BLOOD
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
- (2012) D. Marin et al. BLOOD
- Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
- (2012) Susan Branford et al. JOURNAL OF CLINICAL ONCOLOGY
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive Value of Marker Half-life in Relapsed and Nonrelapsed Nonseminomatous Germ Cell Testicular Tumor Patients Undergoing Chemotherapy
- (2011) Serkan Keskin et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
- (2011) M. Tang et al. BLOOD
- BCR-ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment
- (2011) A. M. Stein et al. CLINICAL CANCER RESEARCH
- Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group
- (2011) Sven-Erik Olofsson et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors
- (2011) Tomohiro Kawaguchi et al. JOURNAL OF NEURO-ONCOLOGY
- Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
- (2011) M Pfirrmann et al. LEUKEMIA
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
- (2010) H. E. White et al. BLOOD
- Regression modeling of competing risk using R: an in depth guide for clinicians
- (2010) L Scrucca et al. BONE MARROW TRANSPLANTATION
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Standardisation of molecular monitoring for chronic myeloid leukaemia
- (2009) Nicholas C.P. Cross BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- (2008) T. P. Hughes et al. BLOOD
- Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- (2008) S. Branford et al. BLOOD
- Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer
- (2008) Isabelle Iwanicki-Caron et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now